NLINKN1 Chip+PRIME.StudySYNCRStentrode+$75M.SeriesDPRECNLayer 7+FDA.BrkthruPARAMArgo+$20M.SeriesBBLKRKNeuroport+200.ImplantsEMTIVMN8+$45M.SeriesBKRNLFlux+Non-invasiveNRBLEHalo+Consumer.BCINEURONeuroPace+RNS.SystemCOGNICognixion+ALS.TrialFUND.YTD2026$2.8B.SectorTRIALSActive50+.ClinTrialsIMPLNTSHumans~100.Intracrtnl
Terminal/Device DB/MoveAgain BCI System
intracorticalbreakthroughinvestigational

MoveAgain BCI System

Implant Type
intracortical
Electrodes
96
Channels
96
FDA Status
breakthrough
Clinical Stage
FDA Breakthrough Device Designation (2021); clinical development
Status
investigational
About

The MoveAgain BCI System is Blackrock Neurotech's wireless, fully implantable brain-computer interface built on the NeuroPort Array platform. Designed to enable immobile patients to control cursors, keyboards, mobile devices, wheelchairs, or prosthetic limbs by thought alone, MoveAgain includes implanted microelectrode arrays that decode motor intent from neuronal activity and transmit signals wirelessly. The system is among the first BCIs to receive FDA Breakthrough Device designation. Patients using Blackrock arrays have controlled robotic arms for self-feeding, typed at 90 characters per minute, and operated wheelchairs.

Target Conditions
ALSquadriplegiaspinal cord injurylocked-in syndrome
Milestones
2021-12FDA Breakthrough Device Designation received
2024-01Tether invests $200M; majority stake acquired
2025-05Axon-R non-invasive headset launched with Cognixion
FDA Regulatory Pathway
Breakthrough Device Designation

FDA Breakthrough Device Designation provides more interactive communication with FDA during development and a priority review pathway. The device is still under investigation and not yet approved for commercial sale.

FDA Device Regulatory Guidance ↗
Other intracortical Devices